Information for Patients and Physicians

Non-Hodgkin lymphoma represents a diverse group of cancers that develop in the lymphatic system and are characterized by uncontrolled growth and accumulation of abnormal lymphocytes. Lymphocytes are a type of white blood cell that are responsible for defending the body against infection. The most common forms of non-Hodgkin lymphoma are follicular (slow growth) and diffuse large B-cell lymphoma (a faster growing subtype). According to the American Cancer Society, about 65,500 people will be diagnosed with non-Hodgkin lymphoma in the United States during 2010.

For more detailed information about the clinical trials summarized below, click on the link to the trial listing at www.clinicaltrials.gov.

NON-HODGKIN LYMPHOMA TRIALS
Brentuximab vedotin (SGN-35) phase II trial for systemic anaplastic large cell lymphoma

Single-arm trial evaluating efficacy and safety of single-agent brentuximab vedotin in 55 relapsed and refractory patients
Enrollment to this trial is complete.

See Study Details ›

Brentuximab vedotin phase II trial for retreatment of patients who previously participated in a brentuximab vedotin study

Evaluating the potential for retreatment with brentuximab vedotin in patients who have relapsed after discontinuing previous brentuximab vedotin therapy

See Study Details ›

Dacetuzumab phase Ib trial for diffuse large B-cell lymphoma

Single-arm trial evaluating safety and activity of dacetuzumab in combination with Rituxan (rituxumab) and Gemzar (gemcitabine) for relapsed and refractory patients
Enrollment to this trial is complete.

See Study Details ›

Dacetuzumab phase Ib trial for indolent non-Hodgkin lymphoma

Single-arm trial evaluating safety and activity of dacetuzumab in combination with Rituxan (rituxumab) for relapsed and refractory indolent non-Hodgkin lymphoma, including follicular lymphoma
Enrollment to this trial is complete.

See Study Details ›

SGN-75 phase I trial for CD70-positive non-Hodgkin lymphoma

Single-agent dose-escalation trial assessing the safety, tolerability, pharmacokinetics and antitumor activity of SGN-75 in patients with metastatic renal cell carcinoma or relapsed or refractory non-Hodgkin lymphoma

See Study Details ›

NON-HODGKIN LYMPHOMA PATIENT RESOURCES

If you have questions about the non-Hodgkin lymphoma clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer, lymphoma and participating in clinical trials can be found on the following web sites.

Privacy Policy  |  Legal Notice